Business Overview - VOQUEZNA aims to transform the landscape of acid-related disorders, targeting a US potential peak revenue opportunity of over $3 billion[11, 12] - The company is experiencing early success with its pricing and access strategy[20] - VOQUEZNA launch is off to a strong start, with over 14,000 total demand[18] Commercial Launch Progress - Over 3,800 filled VOQUEZNA scripts[18] - Over 1,200 unique VOQUEZNA writers[18] - The company has achieved approximately 38% commercial coverage, representing about 60 million commercial lives covered[21] Financial Results - The company had $3814 million in cash as of December 31, 2023[27] - Q4 2023 net revenues were $07 million[27] - Full Year 2023 Non-GAAP R&D expenses were $714 million, and Non-GAAP SG&A expenses were $1010 million[27] - Full Year 2023 GAAP net loss was ($201592) thousand, and Non-GAAP adjusted net loss was ($129713) thousand[29]